Zobrazeno 1 - 5
of 5
pro vyhledávání: '"59"'
Autor:
Mauro D'Amato, Nicholas A. Kennedy, Anette Ocklind, Rahul Kalla, Alex Adams, Dirk Repsilber, Fernando Gomollón, Nicholas T. Ventham, Petr Ricanek, Jonas Christoffer Lindstrøm, Daniel Bergemalm, Fredrik Hjelm, Jonas Halfvarson, Jack Satsangi, Gwo-Tzer Ho, Cecilia Petren, Marie J. Pierik, Simen Vatn, Morten H. Vatn, Johan D. Söderholm, Christine Olbjørn, Jørgen Jahnsen
Publikováno v:
Journal of Crohn's & Colitis, 15(5), 699-708. Oxford University Press
Background Success in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic biomarkers in inflammatory b
Autor:
Leo McCluskey, Pilar Hernandez-Con, Xuemei Huang, Defne A. Amado, Michelle E. Fullard, Richard B. Dewey, Marijan Posavi, John Q. Trojanowski, Maria Diaz-Ortiz, Benjamine Liu, Daniel Weintraub, Andrew Siderowf, Jacqueline Rick, Alice Chen-Plotkin, Christine R. Swanson, R. Tyler Skrinak
Publikováno v:
PLoS Medicine, Vol 16, Iss 10, p e1002931 (2019)
PLoS Medicine
PLoS Medicine
Background Parkinson’s disease (PD) is a progressive neurodegenerative disease affecting about 5 million people worldwide with no disease-modifying therapies. We sought blood-based biomarkers in order to provide molecular characterization of indivi
Autor:
Xuejuan Gao, Hong-Ling Jia, Qi-Fang Song, Xiaoqiong Gu, Li Zhang, Ping Huang, Jing-Jie Jin, Zhou-Ping Wang, Xiao-Fei Xie
Publikováno v:
Cardiology in the Young. 27:1786-1796
BackgroundKawasaki disease, which is characterised by systemic vasculitides accompanied by acute fever, is regularly treated by intravenous immunoglobulin to avoid lesion formation in the coronary artery; however, the mechanism of intravenous immunog
Autor:
Katharina Fink, Carl Hamsten, Sahl Khalid Bedri, Anna Glaser, Ali Manouchehrinia, Jan Hillert, Tomas Olsson, Burcu Ayoglu, Hans Grönlund, Ola Nilsson, Anna Månberg, Peter Nilsson
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217208 (2019)
PLoS ONE
PLoS ONE
Multiple sclerosis (MS) treatment options have improved significantly over the past decades, but the consequences of MS can still be devastating and the needs for monitoring treatment surveillance are considerable. In the current study we used affini
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170741 (2017)
PLoS ONE
PLoS ONE
Idiopathic pulmonary fibrosis (IPF) is a gradual lung disease with a survival of less than 5 years post-diagnosis for most patients. Poor molecular description of IPF has led to unsatisfactory interpretation of the pathogenesis of this disease, resul